Purple Biotech (PPBT) Equity Average (2018 - 2021)

Purple Biotech (PPBT) has disclosed Equity Average for 4 consecutive years, with $72.4 million as the latest value for Q4 2021.

  • On a quarterly basis, Equity Average rose 59.87% to $72.4 million in Q4 2021 year-over-year; TTM through Dec 2021 was $72.4 million, a 59.87% increase, with the full-year FY2021 number at $72.4 million, up 59.87% from a year prior.
  • Equity Average was $72.4 million for Q4 2021 at Purple Biotech, up from $45.3 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $72.4 million in Q4 2021 to a low of $9.8 million in Q4 2018.
  • A 4-year average of $34.6 million and a median of $28.1 million in 2019 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: rose 11.02% in 2019, then soared 314.45% in 2020.
  • Purple Biotech's Equity Average stood at $9.8 million in 2018, then increased by 11.02% to $10.9 million in 2019, then skyrocketed by 314.45% to $45.3 million in 2020, then soared by 59.87% to $72.4 million in 2021.
  • Per Business Quant, the three most recent readings for PPBT's Equity Average are $72.4 million (Q4 2021), $45.3 million (Q4 2020), and $10.9 million (Q4 2019).